Pharmamarketeer

Retrophin’s phase 3 FORT study of fosmetpantotenate in patients with PKAN fails to meet primary endpoint

Retrophin Inc, a biopharmaceutical company specializing in identifying, developing and delivering life─changing therapies to people living with rare disease, announced that the phase 3 FORT study evaluating the safety

Medhc-fases-banner
Advertentie(s)